Discovery Life Sciences

08/12/2026

AstraZeneca’s investigational antibody-drug conjugate (ADC) sonesitatug vedotin (Sone-Ve) improved overall survival in patients with CLDN18.2-positive advanced gastric and gastroesophageal junction cancers.

Evaluated in the CLARITY-Gastric01 Phase 3 trial, Sone-Ve is the first CLDN18.2-targeted ADC to demonstrate positive survival benefit in this setting, highlighting the continued momentum behind targeted ADC approaches in precision oncology.

Read more here: https://www.onclive.com/view/sonesitatug-vedotin-improves-overall-survival-in-second--and-later-line-cldn18-2-positive-gastric-gej-cancer

Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.

08/05/2026

How predictive are your preclinical models?

Join Discovery’s Gary DosSantos 🧬 on August 19 at 2 PM EST, 11:00 AM PDT for a live webinar exploring how primary human blood cell models can generate more predictive drug toxicity and efficacy data to support better decision-making throughout drug development.

Register today:

https://lnkd.in/eXj6tRJM

06/19/2026

Juneteenth is a reminder that freedom is hard won, and that progress requires us to keep showing up. Today, we honor the resilience of Black communities, past and present, and the contributions that continue to shape our world.

06/17/2026

Alzheimer's impacts millions of lives, but meaningful progress is happening every day.

At Discovery, our genomics and proteomics teams are helping researchers better understand what’s happening at the molecular level in Alzheimer’s and other brain diseases.

These insights are key to improving early detection and developing more effective treatments in the future.

This Alzheimer’s & Brain Awareness Month, we’re proud to support the science that brings us closer to better outcomes for patients everywhere.

06/12/2026

Happy Pride Month!

This month, we celebrate the LGBTQ+ community and the diversity that makes our teams, workplaces, and communities stronger. We are proud to support an environment where everyone is welcomed, respected, and encourages to be their authentic self.

Here’s to celebrating inclusion, belonging, and the people who help move science forward every day.

05/14/2026

This AANHPI Heritage Month, we’re celebrating the contributions and impact of Asian American, Native Hawaiian, and Pacific Islander communities in science, healthcare, and beyond.

Innovation happens when diverse perspectives come together, and we’re grateful for the AANHPI professionals who are driving science forward every day. Join us in recognizing and celebrating the people making a difference this month and all year long.

05/06/2026

4,812,000 cancer deaths have been averted since 1991*. A powerful reminder of what sustained investment in research can achieve.

This National Cancer Research Month, we recognize scientists, clinicians, and partners advancing oncology and the progress being made across earlier detection, treatment, and prevention.

Looking ahead, continued innovation across primary patient material, tumoroid models, liquid biopsies, and proteomics will help close critical gaps and move research closer to real-world impact for patients.

*Source: American Cancer Society, Cancer Facts & Figures 2025